Frequently Asked Questions about Arcutis Biotherapeutics, Inc. (ARQT)

Name: Arcutis Biotherapeutics, Inc. (ARQT) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Arcutis Biotherapeutics, Inc. (ARQT) do?

Accepted Answer

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atop...

Question 2

Is Arcutis Biotherapeutics, Inc. (ARQT) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of ARQT reveals an Altman Z-Score of 5.15 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.38B most recent), help investors decide if ARQT fits their risk profile.

Question 3

What is the current P/E ratio for ARQT?

Accepted Answer

As of the latest trading session, Arcutis Biotherapeutics, Inc. (ARQT) has a trailing P/E ratio of -184.90.

Question 4

Who is the CEO of Arcutis Biotherapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Arcutis Biotherapeutics, Inc. is Todd Franklin Watanabe.

Question 5

What was ARQT's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Arcutis Biotherapeutics, Inc. reported annual revenues of $0.38B (2025), $0.20B (2024), $0.06B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does ARQT pay a dividend?

Accepted Answer

Arcutis Biotherapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does ARQT have?

Accepted Answer

In its latest reporting period, Arcutis Biotherapeutics, Inc. generated $-0.01B in Free Cash Flow against a total debt load of $0.01B.

Question 8

What is the Price-to-Book (P/B) ratio of Arcutis Biotherapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Arcutis Biotherapeutics, Inc. (ARQT) is currently 15.75.

Question 9

What is the Price-to-Sales (P/S) ratio of ARQT?

Accepted Answer

Based on trailing twelve-month data, Arcutis Biotherapeutics, Inc. (ARQT) trades at a Price-to-Sales (P/S) ratio of 7.67.

Question 10

What is Arcutis Biotherapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Arcutis Biotherapeutics, Inc. (ARQT) has a Return on Equity (ROE) of -10.26%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	433M	243.5M	189.5M	6.3M	-36.6M
2024-12	348.9M	191.3M	157.5M	110.6M	39.3M
2023-12

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	433M	243.5M	189.5M	6.3M	-36.6M
2024-12	348.9M	191.3M	157.5M	110.6M	39.3M
2023-12